Cord Dohrmann
Chief Tech/Sci/R&D Officer at EVOTEC SE
Net worth: 3 M $ as of 2024-03-30
Profile
Presently, Cord E. Dohrmann holds the position of Chief Scientific Officer at Evotec SE and Co-Managing Director at Evotec International GmbH (a subsidiary of Evotec SE). He is also on the board of Eternygen GmbH and FSHD Unlimited Cooperatie Ua. He previously was Chief Executive Officer of DeveloGen AG, Principal at The General Hospital Corp., Principal at Eberhard Karls Universität Tübingen and Principal at Duke University. Dr. Dohrmann received a graduate degree from Max-Planck-Institute for Molecular Genetics, an undergraduate degree from Eberhard Karls Universität Tübingen and a doctorate from Harvard Medical School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
EVOTEC SE
0.11% | 2022-12-30 | 188,926 ( 0.11% ) | 3 M $ | 2024-03-30 |
Cord Dohrmann active positions
| Companies | Position | Start |
|---|---|---|
| EVOTEC SE | Chief Tech/Sci/R&D Officer | 2010-08-31 |
Eternygen GmbH
 Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | Director/Board Member | - |
FSHD Unlimited Cooperatie Ua
 FSHD Unlimited Cooperatie Ua Pharmaceuticals: MajorHealth Technology FSHD Unlimited Cooperatie Ua is a Dutch pharmaceutical company that specializes in facioscapulohumeral dystrophy. The private company is based in Leiden, the Netherlands and has subsidiaries in the Netherlands. The company was founded by Cornelis van der Graaf. | Director/Board Member | 2017-05-31 |
Evotec International GmbH
 Evotec International GmbH Miscellaneous Commercial ServicesCommercial Services Evotec International GmbH develops and provides drugs for the treatment of CNS disorders. It focuses on Alzheimer's disease and other neurological disorders. The company was founded in 1999 and is headquartered in Hamburg, Germany. | Chief Executive Officer | - |
Breakpoint Therapeutics GmbH
 Breakpoint Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breakpoint Therapeutics GmbH engages in the discovery and development of anti-cancer drugs. It aims to advance to clinical development first-in-class oncology drugs that interfere with DNA repair and replication stress tolerance pathways. The company is headquartered in Hamburg, Germany. | Director/Board Member | - |
| Facio Therapies | Director/Board Member | - |
| German Council of Science & Humanities | Corporate Officer/Principal | - |
Former positions of Cord Dohrmann
| Companies | Position | End |
|---|---|---|
DeveloGen AG
 DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Chief Executive Officer | 2012-01-24 |
| Eberhard Karls Universität Tübingen | Corporate Officer/Principal | - |
| ░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░ ░░░░░░░ ░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Cord Dohrmann
| Eberhard Karls Universität Tübingen | Undergraduate Degree |
| Max-Planck-Institute for Molecular Genetics | Graduate Degree |
| Harvard Medical School | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| EVOTEC SE | Health Technology |
| Private companies | 8 |
|---|---|
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Health Services |
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Health Technology |
Evotec International GmbH
Evotec International GmbH Miscellaneous Commercial ServicesCommercial Services Evotec International GmbH develops and provides drugs for the treatment of CNS disorders. It focuses on Alzheimer's disease and other neurological disorders. The company was founded in 1999 and is headquartered in Hamburg, Germany. | Commercial Services |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | Health Technology |
| Facio Therapies | |
Breakpoint Therapeutics GmbH
Breakpoint Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breakpoint Therapeutics GmbH engages in the discovery and development of anti-cancer drugs. It aims to advance to clinical development first-in-class oncology drugs that interfere with DNA repair and replication stress tolerance pathways. The company is headquartered in Hamburg, Germany. | Health Technology |
| German Council of Science & Humanities | |
FSHD Unlimited Cooperatie Ua
FSHD Unlimited Cooperatie Ua Pharmaceuticals: MajorHealth Technology FSHD Unlimited Cooperatie Ua is a Dutch pharmaceutical company that specializes in facioscapulohumeral dystrophy. The private company is based in Leiden, the Netherlands and has subsidiaries in the Netherlands. The company was founded by Cornelis van der Graaf. | Health Technology |
- Stock Market
- Insiders
- Cord Dohrmann
